T. Rowe Price Associates
LYRA

T. Rowe Price Associates’s LYRA THERAPEUTICS INC LYRA Stock Holding History

T. Rowe Price Associates’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-351
Closed -$3K – 3111
2025
Q1 		$3K Hold
351
– – ﹤0.01% 3035
2024
Q4 		$4K Hold
351
– – ﹤0.01% 3010
2024
Q3 		$5K Hold
351
– – ﹤0.01% 3002
2024
Q2 		$0 Buy
+351
New +$39.7K ﹤0.01% 2982

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates's LYRA Position: Q2 2025 in Review

T. Rowe Price Associates sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 351 shares — an estimated $3K sold.

T. Rowe Price Associates first reported a position in LYRA in Q2 2024 and held it in 4 quarters. The position peaked at $5K in Q3 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • T. Rowe Price Associates reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 351 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $3K.
  • T. Rowe Price Associates first reported a position in LYRA THERAPEUTICS INC in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's LYRA THERAPEUTICS INC position peaked at $5K in Q3 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.